System disruptions
There are recurring service disruptions on some of the search portals due to high traffic. We are working to resolve the issue, you may temporarily encounter an error message.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Chronic polypharmacy impairs explorative behavior and reduces synaptic functions in young adult mice
Show others and affiliations
Number of Authors: 82020 (English)In: Aging, E-ISSN 1945-4589, Vol. 12, no 11, p. 10147-10161Article in journal (Refereed) Published
Abstract [en]

A major challenge in the health care system is the lack of knowledge about the possible harmful effects of multiple drug treatments in old age. The present study aims to characterize a mouse model of polypharmacy, in order to investigate whether long-term exposure to multiple drugs could lead to adverse outcomes. To this purpose we selected five drugs from the ten most commonly used by older adults in Sweden (metoprolol, paracetamol, aspirin, simvastatin and citalopram). Five-month-old wild type male mice were fed for eight weeks with control or polypharmacy diet. We report for the first time that young adult polypharmacy-treated mice showed a significant decrease in exploration and spatial working memory compared to the control group. This memory impairment was further supported by a significant reduction of synaptic proteins in the hippocampus of treated mice. These novel results suggest that already at young adult age, use of polypharmacy affects explorative behavior and synaptic functions. This study underlines the importance of investigating the potentially negative outcomes from concomitant administration of different drugs, which have been poorly explored until now. The mouse model proposed here has translatable findings and can be applied as a useful tool for future studies on polypharmacy.

Place, publisher, year, edition, pages
2020. Vol. 12, no 11, p. 10147-10161
Keywords [en]
polypharmacy, adverse outcomes, memory, behavior, synaptic proteins
National Category
Geriatrics Gerontology, specialising in Medical and Health Sciences Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:su:diva-183630DOI: 10.18632/aging.103315ISI: 000540580800012PubMedID: 32445552OAI: oai:DiVA.org:su-183630DiVA, id: diva2:1456072
Available from: 2020-07-31 Created: 2020-07-31 Last updated: 2024-07-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Wastesson, Jonas W.

Search in DiVA

By author/editor
Wastesson, Jonas W.
By organisation
Aging Research Center (ARC), (together with KI)
In the same journal
Aging
GeriatricsGerontology, specialising in Medical and Health SciencesPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 121 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf